RankingsPricing
  1. US-listed companies
  2. NORTHWEST BIOTHERAPEUTICS INC
  3. Raw

NORTHWEST BIOTHERAPEUTICS INCNWBO

Market cap
$345.05M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-33-67-66-136-115-80-73-36-20-530179-105-63-84
Depreciation and amortization22200001000122
Amortization of debt discount-------7132322
Change in fair value of derivatives--3-151618-31812-435239-2640
Change in fair value of share payable-----------0-00
Change in fair value of convertible notes-------------28
Convertible notes payable---------1-----
Loss from extinguishment of debt------1-130-2-2-0-3-5-14
Loss from issuance of debt--------------1
Operating Lease ROA----------0000
Stock-based compensation for services-------14252151243
Warrant modifications associated with convertible notes under fair value option------------00
Loss from warrant modifications--------------1
Non-cash financing cost-------------1
Subtotal of non-cash charges-----5290-7498-220451317
Prepaid expenses and other current assets-0000-00012-30-1-0
Other non-current assets-00-0-0-01000-100
Accounts payable and accrued expenses7885411-0020309
Related party accounts payable and accrued expenses1328421931884-40-13-41
Lease liabilities----------0000
Net cash used in operating activities-15-23-38-55-79--36-35-32-32-38-53-54-57
Purchase of equipment and construction in progress--------076331
Net cash used in investing activities-0-00-36-7-045-0-8-6-3-3-1
Proceeds from issuance of Series C convertible preferred stock-----------19138
Proceeds from Issuance of Common Stock-------------14
Proceeds from Warrant Exercises---57833214201122
Proceeds from investor advance-----------0-3--0
Proceeds from Notes Payable888--5108793062014
Proceeds from Issuance of Convertible Notes Payable------------1320
Proceeds from contingent payment obligation------------50
Repayment of notes payable000----2026500
Repayment of convertible notes payable134---35-0---1
Repayment of investor advances------------0-
Net cash provided by financing activities1191501998694-348105348425357
Effect of Exchange Rate on Cash and Cash Equivalents-----------6-11
Net increase (decrease) in cash and cash equivalents-------7--22105-8-50
Convertible notes payable------0110--00
Interest payments on notes payable------00------
Cashless warrants and stock options exercise----------0000
Reclassification of warrant liabilities to stockholders' deficit------------76-
Reclassification Of Equity Classified Warrants To Liability-------------1
Issuance of common stock for conversion of debt and accrued interest-------6787122519
Debt Conversion, Converted Instrument, Amount-------500,000------
Conversion of Stock, Amount Converted------------1914
Capital expenditures included in accounts payable---------10100
Issuance Of Convertible Preferred Stock In Lieu Of Debt Redemption-----------31-
Deemed dividend related to warrant modifications------------21
Debt discount related to warrant modifications------------00
Offering cost related to warrant modification associated with a security purchase agreement-------------0
Reclassification between contingent payment obligation and convertible notes payable at fair value-------------0
Reclassification of investor advances to convertible notes payable------------1-
Reclassification Of Investor Advances To Stockholders Deficit------------1-
Reclass earned but unissued milestone shares from equity to liability------------1-
Right-of-use asset recognized in exchange for lease liability-------------0